The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2014 | MRD in myeloma and proteasome inhibition in amyloidosis
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma and amyloidosis. In multiple myeloma, minimum residual disease (MRD) testing is receiving great interest in the evaluation of treatment and as a prognostic marker. In amyloidosis, proteasome inhibition is emerging as an important novel therapy.
